Loading...

Rising Specialty Pharmacy Demand Will Unlock Future Healthcare Potential

Published
18 Jul 24
Updated
07 May 25
AnalystConsensusTarget's Fair Value
US$369.13
19.5% undervalued intrinsic discount
10 Sep
US$296.98
Loading
1Y
-12.8%
7D
4.5%

Author's Valuation

US$369.1319.5% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on07 May 25
Fair value Decreased 9.67%

Shared on30 Apr 25
Fair value Increased 7.52%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on23 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on16 Apr 25
Fair value Increased 0.14%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Increased 5.93%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25
Fair value Increased 0.17%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25
Fair value Decreased 0.98%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on10 Mar 25
Fair value Decreased 3.76%

AnalystConsensusTarget has decreased revenue growth from 6.4% to 3.6%.